Covidien
COV today
announced the launch of a new study, SWIFT PRIME, which enrolled its
first patient at the University at Buffalo. The new multi-center,
randomized controlled trial will be one of the largest global studies to
examine the adjunctive use of mechanical thrombectomy during the early
stages of acute ischemic stroke onset.
Covidien's Solitaire FR Revascularization Device will be used in the SWIFT PRIME Study (Photo: Business Wire)
Acute ischemic stroke occurs when a clot in a blood vessel blocks blood
supply to the brain. According to the American Heart Association, acute
ischemic stroke is the leading cause of disability and the fourth most
common cause
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in